“Welcome to Early stages of Parkinson’s disease”

Primary cortical neuron with staining for MAP2, TGN-46 and DAPI.

Primary cortical neuron with staining for PPP2CA and LRRK2.

CRISPR/Cas9 technology used in the lab to silence or activate transcription in human cells: dCas9-mediated transcriptional modulation of phosphatases.
(A) dCas9 fused to effector domains can serve as an RNA-guided DNA-binding protein to target any protein to any DNA sequence. The effectors used with the catalytically inactive Cas9 (dCas9) are KRAB fusion protein to repress (CRISPRi) or the VP64 fusion protein to activate (CRISPRa) expression has shown on the picture.
(B) Stable suppression and overexpression of PPP1R1B by dCas9-KRAB or dCas9-VP64 in SH-SY5Y cells respectively. Cells stably expressing dCas9-KRAB or VP64 were infected with lentivirus constructs expressing a negative control sgRNA or two different sgRNAs targeting PPP1R1B.

EARLY STAGES OF PARKINSON'S DISEASE
STAFF - TENURED

Dr. BELARBI Karim, Pharm D, PhD
Associate Professor in Neuropharmacology.
University of Lille, Faculty of Pharmacy
Teaching: neurosciences, molecular biology, pharmacology
Research: alpha-synuclein, sphingolipids,neuroinflammation – experimental models.

Dr. VANBESIEN-MAILLIOT Christel, PhD.
Associate Professor (HDR).
University of Lille, Faculty of Sciences and Technologies.
Teaching: Neurosciences, neuropharmacology, molecular and cellular biology.
Research: Impact of pesticides on the development of parkinsonism, transcriptome, Experimental models.
ASSOCIATE PROFESSORS AND PROFESSORS
UNIVERSITY & HOSPITAL-ASSOCIATED

Pr. DESTEE Alain, MD, PhD.
Professor, Hospital Practitioner.
University of Lille, Faculty of Medicine.
Research: Biomarkers, Neurology.
Duties: Consultant, CHRU de Lille, Direction of research Health.
Project Manager at the Evaluation Department of HCERES (Higher Council for the Evaluation of Research and Higher Education).

Pr. GRESSIER Bernard, PharmD, PhD.
University Hospital – Hospital Practitioner.
University of Lille, Faculty of Pharmacy, Pharmacology.
Teaching: experimental and molecular pharmacology.
Research: experimental models, alpha-synuclein, oxydative stress, neuroinflammation.

Dr. KREISLER Alexandre, MD, PhD.
Hospital Practitioner.
Teaching: Movement Pathologies (Institute of Speech-Language Pathology – Postgraduate Education).
Research: Parkinson’s disease, clinical correlation, biomarkers, dystonia.
Hospital Duties: Neurologist.

Dr. MUTEZ Eugénie, MD, PhD.
Hospital Practitioner.
Research: Parkinson disease, clinical correlation, biomarkers, transcriptome.
Hospital duties: Neurologist.

Dr. SIMONIN Clémence, MD, PhD.
Hospital practitioner.
Research: Parkinson and Huntington diseases, clinical correlations, biomarkers.
Hospital duties: Neurologist.
ENGINEER & TECHNICIANS

COMPTDAER Thomas
Technician, University of Lille.

SEMAILLE Pierre
Engineer of the Hospital Center University of Lille.